New therapeutic strategy of Alzheimer's disease

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K07095
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Nerve anatomy/Neuropathology
• Research Institution: Tottori University
• Principal Investigator: KATO Shinsuke 鳥取大学, 医学部, 准教授 (60194817)
• Co-Investigator(Kenkyū-buntansha): 北尾 慎一郎 鳥取大学, 医学部, 助教 (60724804) ; 加藤 雅子 鳥取大学, 医学部, 准教授 (80221183)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: アルツハイマー病 / 画期的新規治療薬 / アルツハイマー病早期発見 / キサンチン酸化還元酵素阻害剤 / 神経変性疾患

Outline of Final Research Achievements

We elucidated the Alzheimer's disease (Alz) mice with mutant amyloid and tau protein genes.New therapeutic drug non-purine XORI: TEI-6720, a control drug purine type (p)XORI:allopurinol (Allop), and placebo: methyl cellulose (MC) were used.In an epoch-making simple cognitive evaluation system, the Alz mice of the both the Allop and the MC groups showed dementia. By contrast, the Alz mice of the TEI-6720 group significantly improved dementia.　Pathological analyses demonstrated that TEI-6720 group showed significantly decreases of both the NFT and the large SP, in a comparison with Allop group or the MC group.

Free Research Field

アルツハイマー病の画期的新規治療薬開発

Academic Significance and Societal Importance of the Research Achievements

アルツハイマー病への臨床応用によりその効果が確認されれば、患者と介護する家族への貢献度は極めて大である。また、国民の医療・福祉の向上に直接結びつき、社会的貢献度は極めて大きい。更に、社会への経済波及効果は計り知れない。